Gapping up
In reaction to strong earnings/guidance:
- LOVE +20.3%, BBBY +15.1% (reports Q4 upside), TSM +4.5%, ALLT +4.4%, BK +4%, BLMN +1.9%, NDLS +1.8% (reports Q1 system-wide comps declined 7.2%), BLK +1.8%, ASH +1.8%, ABT +0.5%
Other news:
- RCUS +50.2% (news reports that GILD is allegedly in discussions to purchase a stake in RCUS)
- AXDX +16% (announces collaboration agreement to distribute the BioCheck MS-FAST and SARS-CoV-2 tests), CGEN +13.4% (getting picked up as RCUS sympathy play as it also has an early-stage Tigit inhibitor)
- URGN +11.7% (receives FDA expedited approval for Jelmyto)
- VNDA +7.5% (enrolls first patient in ODYSSEY trial for severe COVID-19 pneumonia; also initiates study of role of genetic variation in COVID-19 infections)
- XP +7% (reports Q1 key retail performance indicators)
- CODX +6.8% (Co-Diagnostics COVID-19 test technology validated for use on saliva samples)
- LTRPA +5.9% (states that it is not aware of the reasons for the recent volatility in its stock price)
- KBR +4.8% (wins US Air Force contract)
- ACGL +2.4% (provides COVID-19 update; announces loss estimates)
- NVAX +2.1% (to commence Phase 1 vaccine trial COVID-19 with Nucleus Network)
- PFGC +1.1% (stock offering)
- COST +0.9% (increases dividend)
Analyst comments:
- JACK +4.9% (upgraded to Buy from Neutral at BTIG Research)
- AWK +3.7% (upgraded to Buy from Neutral at Goldman)
- FCX +2.5% (upgraded to Overweight from Equal Weight at Barclays )
- AGNC +2.1% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities)
- CGC +1.8% (upgraded to Hold from Underperform at Jefferies)